CT psoas calculations on the prognosis prediction of emergency laparotomy: a single-center, retrospective cohort study in eastern Asian population

Table 4 Patients’ baseline characteristics: Sarcopenia versus Non-Sarcopenia

Baseline characteristic	PML3			PMI (mm²/m²)			PMD (HU/mm²)
Baseline characteristic	Sarcopenia	Non-Sarcopenia	P value	Sarcopenia	Non-Sarcopenia	P value	Sarcopenia	Non-Sarcopenia	P value
Age, years (SD)	67.5 (11.4)	54.6 (15.7)	< 0.001	61.1 (15.2)	56.6 (15.8)	0.063	68.0 (10.4)	54.4 (15.8)	< 0.001
Male gender, n (%)	34 (60.7)	104 (60.5)	0.974	34 (60.7)	104 (60.5)	0.974	34 (60.7)	104 (60.5)	0.974
BMI, kg/m² (SD)	20.8 (3.7)	22.0 (3.4)	0.033	20.0 (3.4)	22.2 (3.4)	< 0.001	21.3 (3.4)	21.8 (3.6)	0.368
ASA score, n (%)			0.028			0.030			0.170
I	0 (0.0)	7 (4.1)		0 (0.0)	7 (4.1)		0 (0.0)	7 (4.1)
II	17 (30.4)	81 (47.1)		19 (33.9)	79 (45.9)		19 (33.9)	79 (45.9)
III	28 (50.0)	68 (39.5)		25 (44.6)	71 (41.3)		30 (53.6)	66 (38.4)
IV	11 (19.6)	15 (8.7)		12 (21.4)	14 (8.1)		7 (12.5)	19 (11.0)
V	0 (0.0)	1 (0.6)		0 (0.0)	1 (0.6)		0 (0.0)	1 (0.6)
Charlson Comorbidities Index, median [IQR]	1.0 [0.0,2.0]	1.0 [0.0,2.0]	0.484	1.0 [0.0,2.0]	1.0 [0.0,2.0]	0.860	1.0 [0.0,2.0]	1.0 [0.0,2.0]	0.111
Previous abdominal surgery, n (%)	20 (35.7)	69 (40.1)	0.558	25 (44.6)	64 (37.2)	0.322	22 (39.3)	67 (39.0)	0.965
Sepsis, n (%)	30 (53.6)	69 (40.1)	0.078	30 (53.6)	69 (40.1)	0.078	31 (55.4)	68 (39.5)	0.038
Malignancy, n (%)	15 (26.8)	29 (16.9)	0.102	20 (35.7)	24 (14.0)	< 0.001	11 (19.6)	33 (19.2)	0.940
ALB, g/L (SD)	34.3 (5.9)	37.8 (6.8)	0.001	33.5 (5.9)	38.1 (6.7)	< 0.001	34.0 (5.9)	37.9 (6.8)	< 0.001
Hb, g/L (SD)	117.7 (26.9)	122.7 (28.6)	0.248	117.1 (27.6)	122.9 (28.3)	0.178	118.0 (23.4)	122.7 (30.0)	0.280

Baseline characteristic	TPG (AU)			PBSA (mm²/m²)
Baseline characteristic	Sarcopenia	Non-Sarcopenia	P value	Sarcopenia	Non-Sarcopenia	P value
Age, years (SD)	65.8 (12.6)	55.1 (15.8)	< 0.001	63.1 (14.0)	56.0 (15.9)	0.003
Male gender, n (%)	34 (60.7)	104 (60.5)	0.974	34 (60.7)	104 (60.5)	0.974
BMI, kg/m² (SD)	20.4 (3.1)	22.1 (3.5)	0.002	21.2 (3.6)	21.8 (3.5)	0.220
ASA score, n (%)			0.090			0.003
I	0 (0.0)	7 (4.1)		0 (0.0)	7 (4.1)
II	20 (35.7)	78 (45.3)		16 (28.6)	82 (47.7)
III	25 (44.6)	71 (41.3)		27 (48.2)	69 (40.1)
IV	11 (19.6)	15 (8.7)		13 (23.2)	13 (7.6)
V	0 (0.0)	1 (0.6)		0 (0.0)	1 (0.6)
Charlson Comorbidities Index, median [IQR]	1.0 [0.0,2.0]	1.0 [0.0,2.0]	0.353	1.0 [0.0,2.0]	1.0 [0.0,2.0]	0.257
Previous Abdominal Surgery, n (%)	23 (41.1)	66 (38.4)	0.719	26 (46.4)	63 (36.6)	0.192
Sepsis, n (%)	31 (55.4)	68 (39.5)	0.038	33 (58.9)	66 (38.4)	0.007
Malignancy, n (%)	15 (26.8)	29 (16.9)	0.102	35.7	14.0	< 0.001
ALB, g/L (SD)	33.8 (5.4)	38.0 (6.9)	< 0.001	33.8 (6.02)	38.0 (6.7)	< 0.001
Hb, g/L (SD)	116.6 (27.2)	123.1 (28.4)	0.136	119.0 (26.8)	122.3 (28.6)	0.442

PML3 psoas muscle to L3 vertebral body ratio, PMI psoas muscle index, PMD psoas muscle density, TPG total psoas gauge, PBSA psoas muscle to body face area ratio, BMI body mass index, ASA American Society of Anesthesiologists, IQR interquartile range, ALB albumin, HB hemoglobin
P value < 0.05 was considered statistically significant

ISSN: 1749-7922